Dallas, TX -- (SBWIRE) -- 08/25/2014 -- The report Global Multiple Sclerosis Drugs Market 2014-2018 says one of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis.
According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market.
Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems. Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.
Buy a copy of report directly @ http://www.reportsnreports.com/purchase.aspx?name=296075.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.
The Global Multiple Sclerosis Drugs Market 2014-2018 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
The report recognizes the following companies as the key players in the Global Multiple Sclerosis Drugs Market: Bayer AG, Biogen Idec Inc., Merck Serono SA, Novartis AG and Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors in the market are: AB Science, Abbvie, Acorda, Active Biotech, GlaxoSmithKline, Glenmark, Mitsubishi Tanabe, Opexa, Pfizer and Sanofi.
Market Driver
- Unmet Medical Needs
- For a full, detailed list, view our report
Market Trend
- Introduction of Disease-modifying Drugs
- For a full, detailed list, view our report
Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease.
Key Questions Answered in this Report
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?